These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

645 related items for PubMed ID: 22190222

  • 1. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer.
    Kim SJ, Lee KE, Myong JP, Park JH, Jeon YK, Min HS, Park SY, Jung KC, Koo do H, Youn YK.
    World J Surg; 2012 Feb; 36(2):310-7. PubMed ID: 22190222
    [Abstract] [Full Text] [Related]

  • 2. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAFV600E mutation.
    Lee YK, Park KH, Park SH, Kim KJ, Shin DY, Nam KH, Chung WY, Lee EJ.
    Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011
    [Abstract] [Full Text] [Related]

  • 3. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.
    Pelizzo MR, Dobrinja C, Casal Ide E, Zane M, Lora O, Toniato A, Mian C, Barollo S, Izuzquiza M, Guerrini J, De Manzini N, Merante Boschin I, Rubello D.
    Biomed Pharmacother; 2014 May; 68(4):413-7. PubMed ID: 24721322
    [Abstract] [Full Text] [Related]

  • 4. [Correlation between BRAF V600E mutation and clinicopathologic features of papillary thyroid carcinoma].
    Lu H, Qiu T, Ying J, Guo C, Lyn N.
    Zhonghua Bing Li Xue Za Zhi; 2014 Dec; 43(12):794-8. PubMed ID: 25623974
    [Abstract] [Full Text] [Related]

  • 5. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
    Gouveia C, Can NT, Bostrom A, Grenert JP, van Zante A, Orloff LA.
    JAMA Otolaryngol Head Neck Surg; 2013 Nov; 139(11):1164-70. PubMed ID: 24030686
    [Abstract] [Full Text] [Related]

  • 6. BRAFV600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma.
    Ahn D, Park JS, Sohn JH, Kim JH, Park SK, Seo AN, Park JY.
    Auris Nasus Larynx; 2012 Apr; 39(2):198-203. PubMed ID: 21862261
    [Abstract] [Full Text] [Related]

  • 7. Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers.
    Han PA, Kim HS, Cho S, Fazeli R, Najafian A, Khawaja H, McAlexander M, Dy B, Sorensen M, Aronova A, Sebo TJ, Giordano TJ, Fahey TJ, Thompson GB, Gauger PG, Somervell H, Bishop JA, Eshleman JR, Schneider EB, Witwer KW, Umbricht CB, Zeiger MA.
    Thyroid; 2016 Apr; 26(4):532-42. PubMed ID: 26950846
    [Abstract] [Full Text] [Related]

  • 8. Role and relevance of BRAF mutations in risk stratifying patients of papillary thyroid cancers along with a review of literature.
    Krishnamurthy A, Ramshankar V, Murherkar K, Vidyarani S, Raghunandhan GC, Das A, Desai PB, Albert K.
    Indian J Cancer; 2017 Apr; 54(1):372-378. PubMed ID: 29199726
    [Abstract] [Full Text] [Related]

  • 9. [Study on the correlation between BRAF(V600E) mutation and lymphatic metastases in papillary thyroid cancer staged preoperativelv as N0].
    Gao Q, Zhang W, Wang N, Duan H, Zhou Y, Zhang W, Zhao D.
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Dec; 29(23):2048-52. PubMed ID: 27101676
    [Abstract] [Full Text] [Related]

  • 10. Risk and Prognostic Factors for BRAFV600E Mutations in Papillary Thyroid Carcinoma.
    Wei X, Wang X, Xiong J, Li C, Liao Y, Zhu Y, Mao J.
    Biomed Res Int; 2022 Dec; 2022():9959649. PubMed ID: 35647194
    [Abstract] [Full Text] [Related]

  • 11. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
    Fraser S, Go C, Aniss A, Sidhu S, Delbridge L, Learoyd D, Clifton-Bligh R, Tacon L, Tsang V, Robinson B, Gill AJ, Sywak M.
    World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
    [Abstract] [Full Text] [Related]

  • 12. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.
    Huang M, Yan C, Xiao J, Wang T, Ling R.
    Diagn Pathol; 2019 Jul 12; 14(1):74. PubMed ID: 31300059
    [Abstract] [Full Text] [Related]

  • 13. Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer?
    Nam JK, Jung CK, Song BJ, Lim DJ, Chae BJ, Lee NS, Park WC, Kim JS, Jung SS, Bae JS.
    Am J Surg; 2012 Apr 12; 203(4):436-41. PubMed ID: 21803329
    [Abstract] [Full Text] [Related]

  • 14. BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness.
    Kurtulmus N, Duren M, Ince U, Cengiz Yakicier M, Peker O, Aydın O, Altiok E, Giray S, Azizlerli H.
    Endocrine; 2012 Oct 12; 42(2):404-10. PubMed ID: 22426956
    [Abstract] [Full Text] [Related]

  • 15. Associations of the BRAF(V600E) mutation with sonographic features and clinicopathologic characteristics in a large population with conventional papillary thyroid carcinoma.
    Park AY, Son EJ, Kim JA, Youk JH, Park YJ, Park CS, Chang HS.
    PLoS One; 2014 Oct 12; 9(10):e110868. PubMed ID: 25337709
    [Abstract] [Full Text] [Related]

  • 16. Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma.
    Jung YY, Yoo JH, Park ES, Kim MK, Lee TJ, Cho BY, Chung YJ, Kang KH, Ahn HY, Kim HS.
    Pathol Res Pract; 2015 Feb 12; 211(2):162-70. PubMed ID: 25468810
    [Abstract] [Full Text] [Related]

  • 17. The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors.
    Choi SY, Park H, Kang MK, Lee DK, Lee KD, Lee HS, Kim SW, Lee EN, Hong JC.
    World J Surg Oncol; 2013 Nov 14; 11():291. PubMed ID: 24228637
    [Abstract] [Full Text] [Related]

  • 18. BRAF V600E Mutation Lacks Association with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma.
    Lai HF, Hang JF, Kuo PC, Kuo CS, Yao SF, Chen JY, Lee CH.
    Ann Surg Oncol; 2024 May 14; 31(5):3495-3501. PubMed ID: 38300401
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.